SEC Form 4 · accession 0000899243-18-002335
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Pomerantz
Officer — President and CEO · Director
Period of report
Jan 30, 2018
Accepted (ET)
Jan 30, 2018 · 9:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.42 | Jan 30, 2018 | A | 278,000 | D | — | Jan 29, 2028 | Common Stock | 278,000 | 278,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter.